1. Home
  2. MMC vs REGN Comparison

MMC vs REGN Comparison

Compare MMC & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MMC
  • REGN
  • Stock Information
  • Founded
  • MMC 1871
  • REGN 1988
  • Country
  • MMC United States
  • REGN United States
  • Employees
  • MMC N/A
  • REGN N/A
  • Industry
  • MMC Specialty Insurers
  • REGN Biotechnology: Pharmaceutical Preparations
  • Sector
  • MMC Finance
  • REGN Health Care
  • Exchange
  • MMC Nasdaq
  • REGN Nasdaq
  • Market Cap
  • MMC 108.4B
  • REGN 110.0B
  • IPO Year
  • MMC N/A
  • REGN 1991
  • Fundamental
  • Price
  • MMC $227.79
  • REGN $738.00
  • Analyst Decision
  • MMC Hold
  • REGN Buy
  • Analyst Count
  • MMC 16
  • REGN 24
  • Target Price
  • MMC $223.56
  • REGN $1,110.63
  • AVG Volume (30 Days)
  • MMC 1.7M
  • REGN 887.5K
  • Earning Date
  • MMC 10-17-2024
  • REGN 10-31-2024
  • Dividend Yield
  • MMC 1.43%
  • REGN N/A
  • EPS Growth
  • MMC 16.97
  • REGN 15.31
  • EPS
  • MMC 8.11
  • REGN 40.43
  • Revenue
  • MMC $23,945,000,000.00
  • REGN $13,847,100,000.00
  • Revenue This Year
  • MMC $7.79
  • REGN $10.13
  • Revenue Next Year
  • MMC $9.51
  • REGN $4.00
  • P/E Ratio
  • MMC $28.10
  • REGN $18.25
  • Revenue Growth
  • MMC 7.84
  • REGN 5.72
  • 52 Week Low
  • MMC $184.28
  • REGN $735.95
  • 52 Week High
  • MMC $232.32
  • REGN $1,211.20
  • Technical
  • Relative Strength Index (RSI)
  • MMC 59.75
  • REGN 13.13
  • Support Level
  • MMC $220.15
  • REGN $735.95
  • Resistance Level
  • MMC $224.57
  • REGN $757.56
  • Average True Range (ATR)
  • MMC 3.56
  • REGN 18.56
  • MACD
  • MMC 0.40
  • REGN -1.24
  • Stochastic Oscillator
  • MMC 80.94
  • REGN 1.89

About MMC Marsh & McLennan Companies Inc.

Marsh McLennan is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (a management and economic consultancy). About half of its revenue is generated outside the US.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).

Share on Social Networks: